Navigation Links
EvaluatePharma Japan KK - Now Open for Business in Tokyo
Date:9/15/2011

LONDON and TOKYO, September 15, 2011 /PRNewswire/ --

EvaluatePharma Ltd, the research company, is delighted to announce the official launch of EvaluatePharma Japan KK.  With a team based in Tokyo, EvaluatePharma Japan KK will be ideally placed to support our clients and prospects in Japan.

"Japan is a very important market for us.  We have managed to build close relationships with our major customers from a distance, but it is now time for us to show our commitment to the Japanese market with a dedicated local operation," said CEO Dr Jonathan de Pass.

With the establishment of EvaluatePharma Japan KK, we welcome Hiroshi Yamazaki, who has joined as a regional director. Mr. Yamazaki is responsible for development of EvaluatePharma's business in Japan.  With many years' experience servicing the pharmaceutical industry, he and the EvaluatePharma Japan team are well positioned to expand and support the business in this territory.

The launch was marked with a reception at the British Embassy in Tokyo, where Dr Jonathan de Pass, founder and CEO of EvaluatePharma Ltd, presented "Darwin's Medicine - Survival of the Fittest in the Pharma Industry."  Drawing on EvaluatePharma's World Preview 2016 (2011 edition), and "The Future of Pharma" by Professor Brian D. Smith, Dr de Pass discussed the evolutionary forces shaping the pharmaceuticals industry in the face of catastrophic loss of revenue post "patent cliff" and the alarming decline in R&D productivity.

Notes to editors

About EvaluatePharma ® - http://www.evaluatepharma.com

Set up in 1996 by former top pharma analyst Dr. Jonathan de Pass, EvaluatePharma® is the premier source for pharma and biotech analysis.

EvaluatePharma was the first company to supply reliable consensus forecasts of global drug sales and now provides standardised worldwide financial and forecast models with consensus product forecasts to 2016, data on R&D pipelines, licensing deals, patent risk and M&A deals, along with analytical tools that include Merge Company and Peer Group Analyzer and NPV (Net Present Value) analysis for more than 3000 products.

Launched in 2007, EvaluatePharma®Alpha offers an off-the-shelf valuation service to quantify the impact of market events on product, portfolio and company valuation - NPV Analyzer, Calendar of Events and the daily news service EP Vantage.


'/>"/>
SOURCE EvaluatePharma Ltd
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. EYLEAâ„¢ (aflibercept injection) Submitted in Japan for Marketing Authorization for the Treatment of Wet Age-Related Macular Degeneration
2. Reverse NanoJapan: Rice to host 25-30 Japanese students
3. Cellectis bioresearch Appoints Wako as Exclusive Distributor of its Genome Customization Solutions in Japan
4. Epichem and AR Brown Sign Exclusive Distribution Agreement for Japan, Taiwan, China and South Korea
5. Silence Therapeutics Issued Japanese Patent Covering its Core RNA Interference (RNAi) Technology
6. The Center for Business Intelligence Donates to the American Red Cross, Matching Employee Contributions for Disaster Relief in Japan
7. 50,000 Potassium Iodide Pills Donated to Japan
8. UBM Announces Content for 10th Annual Japanese Pharma & Bio Events
9. Reportlinker Adds The 2011 Clinical Chemistry and Immunodiagnostics Markets: US, Europe, Japan; Product Development Opportunities and Business Expansion Strategies for Instrument and Reagent Suppliers
10. Reportlinker Adds The 2011 Blood Banking Market: US, Europe, Japan - Emerging Opportunities and Business Expansion Strategies for Suppliers
11. Reportlinker Adds The 2011 Immunoprotein Diagnostics Market: US, Europe, Japan Test Volume and Sales Forecasts by Country and Market Segment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... 2016  Global demand for enzymes is forecast ... to $7.2 billion.  This market includes enzymes used ... biofuel production, animal feed, and other markets) and ... Food and beverages will remain the largest market ... of products containing enzymes in developing regions.  These ...
(Date:6/27/2016)... Raleigh, NC (PRWEB) , ... June 27, 2016 ... ... a mission to bring innovative medical technologies, services and solutions to the healthcare ... development and implementation of various distribution, manufacturing, sales and marketing strategies that are ...
(Date:6/24/2016)... June 24, 2016 Epic Sciences unveiled ... cancers susceptible to PARP inhibitors by targeting homologous ... (CTCs). The new test has already been incorporated ... multiple cancer types. Over 230 clinical ... response pathways, including PARP, ATM, ATR, DNA-PK and ...
(Date:6/23/2016)...   Boston Biomedical , an industry leader ... target cancer stemness pathways, announced that its lead ... Designation from the U.S. Food and Drug Administration ... gastroesophageal junction (GEJ) cancer. Napabucasin is an orally ... stemness pathways by targeting STAT3, and is currently ...
Breaking Biology Technology:
(Date:6/16/2016)... , June 16, 2016 ... is expected to reach USD 1.83 billion by ... View Research, Inc. Technological proliferation and increasing demand ... are expected to drive the market growth. ... The development of advanced multimodal techniques ...
(Date:6/3/2016)... LONDON , June 3, 2016 /PRNewswire/ ... Transport Management) von Nepal ... ,Angebot und Lieferung hochsicherer geprägter Kennzeichen, einschließlich ... weltweit führend in der Produktion und Implementierung ... an der Ausschreibung im Januar teilgenommen, aber ...
(Date:5/24/2016)... 2016 Ampronix facilitates superior patient care by providing unparalleled technology to leaders ... is the latest premium product recently added to the range of products distributed by ... ... ... LCD Medical Display- Ampronix News ...
Breaking Biology News(10 mins):